Detecting diminished dopamine-firing cells could reveal earliest signs of Alzheimer's disease
- Sheffield scientists discover a loss of cells that use dopamine may cause part of the brain - responsible for forming new memories - to function less effectively
- Findings could revolutionise screening for Alzheimer’s disease which affects more than 520,000 people in the UK
- First study to demonstrate such a link in humans
A new link between diminished input from dopamine-firing cells deep inside the brain and the ability to form new memories could be crucial in detecting the earliest signs of Alzheimer’s disease.
Scientists from the National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre at the University of Sheffield have discovered a loss of cells that use dopamine – a neurotransmitter that has a number of functions including regulating movement and emotional responses – may cause the part of the brain responsible for forming new memories to function less effectively.
The findings could revolutionise screening for the early signs of Alzheimer’s disease – which affects more than 520,000 people in the UK – changing the way brain scans are acquired and interpreted as well as using different memory tests.
Lead author of the study, Professor Annalena Venneri, from the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield, said: “Our findings suggest that if a small area of brain cells, called the ventral tegmental area, does not produce the right amount of dopamine for the hippocampus, a small organ located within the brain’s temporal lobe, it will not work efficiently.
“The hippocampus is associated with forming new memories, therefore these findings are crucial to the early detection of Alzheimer’s disease. The results point at a change which happens very early on, which might trigger Alzheimer’s disease.
“This is the first study to demonstrate such a link in humans.”
Professor Venneri and fellow lead author Dr Matteo De Marco acquired 3Tesla Magnetic Resonance Imaging (MRI) scans on 51 healthy adults, 30 patients with a diagnosis of mild cognitive impairment, and 29 patients with a diagnosis of Alzheimer’s disease. 3Tesla MRIs are twice the normal strength of normal MRI scans generating the highest quality images.
The results showed a key link between the size and function of the ventral tegmental area, the size of the hippocampus and the ability to learn new material.
“More studies are necessary, but these findings could potentially lead to a new way of screening the elderly population for early signs of Alzheimer’s disease, changing the way brain scans are acquired and interpreted and using different memory tests,” said Professor Venneri who is also an Honorary Consultant at Sheffield Teaching Hospital NHS Foundation Trust.
“Another possible benefit is that it might lead to a different treatment option with the potential to change or halt the course of the disease very early, before major symptoms manifest.
“We now want to establish how early alterations in the ventral tegmental area can be seen and also test whether these alterations can be counteracted with treatments already available.”
The results of the study are published today (27 March 2018) in the Journal of Alzheimer’s Disease.
This study has been completed at the NIHR Biomedical Research Centre (BRC) in Sheffield which is dedicated to translational neuroscience for chronic neurological disorders. The Centre was launched in April 2017.
The NIHR Sheffield Biomedical Research Centre is a research partnership between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, dedicated to improving the treatment and care of people living with chronic neurological disorders.
The University of Sheffield and Parkinson’s UK have launched a new £1 million virtual biotech company in the next stage of a pioneering research programme to create new drugs for Parkinson’s.
We received the great news last month that our bid to create a new BRC in Sheffield was successful with funding of £4,049,681 to be awarded over 5 years from April 2017. Our BRC Executive Group will soon begin the contractual negotiations with NIHR to initiate our programme of research in Translational Neuroscience for Chronic Neurological Disorders.
Promoting the discovery of new treatments for Hereditary Spastic Paraplegia
Categorised under: research
The inter-faculty genomic medicine team led by Professor Winston Hide have won a competitive bid to provide the UK’s first dedicated masters course in genomic medicine for NHS Health Education England (HEE). This award has only been made to top genomics centres of excellence in the UK.
Anyone, with or without dementia, can register their interest in taking part in dementia research as a volunteer with the new initiative that is being rolled out nationwide.
New research from the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust found that only half of patients seen at neurology-led memory clinics at the Royal Hallamshire Hospital suffered with dementia.
New lead for potential Parkinson’s treatment: Effects of high-risk Parkinson’s mutation are reversible
Researchers from the University of Sheffield have found vital new evidence on how to target and reverse the effects caused by one of the most common genetic causes of Parkinson’s.
rofessor Annalena Venneri, Head of the Translational Neuropsychology Group, has been appointed as the new Scientific Director of the Institute for Research, Hospitalisation and Health Care (IRCCS) San Camillo Hospital in Venice.
A key piece of equipment for SITraN has been generously funded by the Sheffield based charity Neurocare and is now being installed at the Sheffield Institute for Translational Neuroscience (SITraN).
A world-leading University of Sheffield academic who is at the forefront of research and treatment into devastating debilitating diseases has been named a Dame Commander of the Order of the British Empire in the Queen’s New Year’s Honours List.